March 30 (Reuters) – The U.S. Food and Drug Administration has cleared Jazz Pharmaceuticals Plc’s drug to treat a rare kind of liver disease, making it the first treatment to win U.S. approval for…
The post Jazz Pharmaceuticals’ rare liver disorder drug wins U.S. approval appeared first on NASDAQ.